Arsenic compounds in cancer therapy: mechanistic insights and antitumor activity

Area of Science:

• Oncology
• Toxicology
• Pharmacology

Background:

• Arsenic (As) is a metalloid with historical medicinal use, despite its toxicity and carcinogenicity.
• Arsenic trioxide (ATO) is a key therapeutic for acute promyelocytic leukemia (APL) in combination therapy.
• Emerging evidence suggests broader applications for arsenic compounds in cancer treatment.

Purpose of the Study:

• To review the therapeutic applications of arsenic compounds in cancer therapy.
• To elucidate the diverse anti-tumor mechanisms of inorganic and organic arsenic compounds.
• To highlight recent advancements in arsenic-based cancer treatments.

Main Methods:

• Literature review of arsenic compounds in cancer therapy.
• Analysis of anti-tumor mechanisms including differentiation induction, anti-angiogenesis, and ROS production.
• Examination of recent clinical and preclinical studies on arsenic in various malignancies.

Main Results:

• Arsenic compounds demonstrate anti-tumor effects via multiple pathways.
• Mechanisms include promoting tumor cell differentiation, inhibiting angiogenesis, and inducing cell cycle arrest.
• Arsenic compounds show potential against both hematologic and solid tumors.

Conclusions:

• Arsenic compounds possess significant therapeutic potential in oncology.
• Understanding their mechanisms of action is crucial for developing novel cancer therapies.
• Further research into arsenic-based treatments may expand their role in managing diverse cancers.